Does the CRNX Form 4 show indirect share ownership through family trusts?

Yes. The filing lists indirect Common Stock holdings through four separate family trusts and the CEO’s spouse. Each trust and the spouse account has its own reported share balance, indicating portions of the overall economic interest are held via related entities.

What does this CRNX Form 4 indicate about the CEO’s direct share ownership?

The Form 4 reports 426,759 shares of Common Stock held directly following the RSU grant. This figure represents the CEO’s direct holdings separate from shares held indirectly through family trusts and a spouse, which are disclosed in additional lines.

Crinetics CEO granted options and RSUs

Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings. He received a stock option for 228,000 shares of Common Stock at an exercise price of $0.00, vesting in forty-eight equal monthly installments starting on February 23, 2026. He also received 62,000 restricted stock units, which vest 25% annually beginning on March 1, 2027. The filing also reflects indirect ownership of Common Stock through four family trusts and a spouse, with separate reported balances for each entity.

Insider Trade Summary

Grant/Award: 290,000 shares

Grant/Award 7 txns

Insider Struthers Richard Scott

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	228,000	$0.00	$0.00
Grant/Award	Common Stock	62,000	$0.00	$0.00
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 228,000 contracts (Direct); Common Stock — 426,759 shares (Direct); Common Stock — 661,205 shares (Indirect, By Family Trust 1); Common Stock — 106,000 shares (Indirect, By Family Trust 2); Common Stock — 110,000 shares (Indirect, By Family Trust 3); Common Stock — 100,000 shares (Indirect, By Family Trust 4); Common Stock — 1,000 shares (Indirect, By Spouse)

Footnotes (2)

F1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
F2. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did the CRNX CEO receive in this Form 4 filing?

The CEO received a stock option for 228,000 shares and 62,000 restricted stock units. The option vests monthly over four years, while the RSUs vest 25% annually starting in 2027, aligning compensation with long-term company performance.

How do the new stock options for the CRNX CEO vest over time?

The 228,000-share stock option vests in forty-eight equal monthly installments starting February 23, 2026. This means the CEO gains exercisable option rights gradually over four years, tying potential benefit to continued service and long-term value creation.

What is the vesting schedule for the 62,000 RSUs granted to the CRNX CEO?

The 62,000 restricted stock units vest 25% annually beginning March 1, 2027. Each year, one-quarter of the units converts into shares of Common Stock, creating a multi-year incentive structure focused on future performance and retention.

Are the equity awards to the CRNX CEO open-market purchases or grants?

They are grants, not open-market purchases. Both the 228,000-share stock option and the 62,000 restricted stock units are reported with a transaction code for grant or award, at a stated price of $0.00 per share, reflecting compensatory awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/25/2026 - 04:37 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Struthers Richard Scott

(Last)

(First)

(Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/23/2026		A		62,000	A	$0⁽¹⁾	426,759	D
Common Stock								661,205	I	By Family Trust 1
Common Stock								106,000	I	By Family Trust 2
Common Stock								110,000	I	By Family Trust 3
Common Stock								100,000	I	By Family Trust 4
Common Stock								1,000	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$43.79	02/23/2026		A		228,000		⁽²⁾	02/23/2036	Common Stock	228,000	$0	228,000	D

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.

2. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR